MCS CEO Adi Dagan: The California hospital will use ActiveCare instead of drug treatments for deep vein thrombosis.
MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL) has sold its ActiveCare system, a non-invasive treatment for deep vein thrombosis, to a medical center in northern California. The company did not disclose the value of the deal or the name of the buyer. Six US medical centers are already using ActiveCare.
MCS CEO Adi Dagan said that the California hospital would use ActiveCare instead of drug treatments for deep vein thrombosis. He added that the sale was part of the company's strategy to market its product to leading medical centers, after clinical trials demonstrated that ActiveCare was as effective as the drug, Lovenox in treating deep vein thrombosis.
MCS's share rose 4.8% by mid-afternoon to NIS 2.20, giving a market cap of NIS 75 million.
Published by Globes [online], Israel business news - www.globes-online.com - on November 18, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009